Osmotica Pharmaceuticals Stock Price

0.00 (0.0%)
Volume 0
Bid Price 1.09
Ask Price 1.15
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Osmotica Pharmaceuticals PLC OSMT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.11 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.9801 - 4.38
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.11 USD


Draw Mode:

Osmotica Pharmaceuticals PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 92.45M 83.29M 40.88M $ 177.88M $ -116.41M -1.31 -0.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.68M 3.90%

more financials information »

Osmotica Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OSMT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months1.,5590.000.0%
1 Year3.034.380.98011.98627,550-1.92-63.37%
3 Years3.809.670.98013.99479,234-2.69-70.79%
5 Years9.009.900.98014.05401,923-7.89-87.67%

Osmotica Pharmaceuticals Description

Osmotica Pharmaceuticals PLC is a fully-integrated biopharmaceutical company. It is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica has a late-stage development pipeline by two NDA candidates that recently completed Phase III clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVL-1201 for the treatment of acquired blepharoptosis, or droopy eyelid.

Your Recent History
Osmotica P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.